Cargando…

Mechanism of Action of Natural Dipeptidyl Peptidase-IV Inhibitors (Berberine and Mangiferin) in Experimentally Induced Diabetes with Metabolic Syndrome

BACKGROUND: Berberine (BER) and mangiferin are known natural dipeptidyl peptidase (DPP-IV) inhibitors. Hence, the study was designed to elucidate the mechanism of action of natural DPP-IV inhibitors (BER and MNG) in experimentally induced diabetes with metabolic syndrome. AIM: The aim of this study...

Descripción completa

Detalles Bibliográficos
Autores principales: Suman, Rajesh Kumar, Borde, Manjusha K, Mohanty, Ipseeta Ray, Singh, Hemant Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10666829/
https://www.ncbi.nlm.nih.gov/pubmed/38023603
http://dx.doi.org/10.4103/ijabmr.ijabmr_115_23
_version_ 1785139125747187712
author Suman, Rajesh Kumar
Borde, Manjusha K
Mohanty, Ipseeta Ray
Singh, Hemant Kumar
author_facet Suman, Rajesh Kumar
Borde, Manjusha K
Mohanty, Ipseeta Ray
Singh, Hemant Kumar
author_sort Suman, Rajesh Kumar
collection PubMed
description BACKGROUND: Berberine (BER) and mangiferin are known natural dipeptidyl peptidase (DPP-IV) inhibitors. Hence, the study was designed to elucidate the mechanism of action of natural DPP-IV inhibitors (BER and MNG) in experimentally induced diabetes with metabolic syndrome. AIM: The aim of this study was to observe mechanism through which natural DPP-IV inhibitor works in diabetes with metabolic syndrome rat model. MATERIALS AND METHODS: Wistar rats were fed high-fat diet for 10 weeks and challenged with streptozotocin (STZ) (40 mg/kg) at the 3(rd) week (high-fat diabetic control [HF-DC] group). After the confirmation of metabolic syndrome in the setting of diabetes, monotherapy (metformin [MET], vildagliptin [VIL], BER, and MNG) and combination (MET + VIL, MET + BER, and MET + MNG) therapy was orally fed to these rats from the 4(th) to 10(th) weeks. RESULTS: Insulin resistance (IR) was seen in the HF-DC group as indicated by raised homeostasis model assessment of IR (HOMA-IR) in HF-DC group as compared with normal control (NC) groups. The treatment groups reduced IR as shown by a decrease in HOMA-IR as compared with HF-DC group rats. The marked reduction (P < 0.001) of beta-cell function was observed in the HF-DC group as a reduced level of HOMA for beta-cell function (HOMA-β) was found as compared with the NC group. Increases in HOMA-β as compared to the HFDC group were observed in the therapy groups. The treatment group significantly reduced cholesterol and atherogenic index. The treatment group showed significant preservation of beta-cell mass as per immunohistochemistry and significant anti-apoptotic activity as per Terminal Deoxyribonucleotidyl Transferase-Mediated dUTP Nick End Labeling assay report. The treated rats significantly (P < 0.05) reduced high-sensitivity C-reactive protein. Lipid peroxidation (thiobarbituric acid reactive substances) marker (P < 0.001) was significantly reduced in the treatment group. CONCLUSION: The natural DPP-IV inhibitors BER and MNG treatment showed beneficial effects on various components of metabolic syndrome.
format Online
Article
Text
id pubmed-10666829
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-106668292023-07-01 Mechanism of Action of Natural Dipeptidyl Peptidase-IV Inhibitors (Berberine and Mangiferin) in Experimentally Induced Diabetes with Metabolic Syndrome Suman, Rajesh Kumar Borde, Manjusha K Mohanty, Ipseeta Ray Singh, Hemant Kumar Int J Appl Basic Med Res Original Article BACKGROUND: Berberine (BER) and mangiferin are known natural dipeptidyl peptidase (DPP-IV) inhibitors. Hence, the study was designed to elucidate the mechanism of action of natural DPP-IV inhibitors (BER and MNG) in experimentally induced diabetes with metabolic syndrome. AIM: The aim of this study was to observe mechanism through which natural DPP-IV inhibitor works in diabetes with metabolic syndrome rat model. MATERIALS AND METHODS: Wistar rats were fed high-fat diet for 10 weeks and challenged with streptozotocin (STZ) (40 mg/kg) at the 3(rd) week (high-fat diabetic control [HF-DC] group). After the confirmation of metabolic syndrome in the setting of diabetes, monotherapy (metformin [MET], vildagliptin [VIL], BER, and MNG) and combination (MET + VIL, MET + BER, and MET + MNG) therapy was orally fed to these rats from the 4(th) to 10(th) weeks. RESULTS: Insulin resistance (IR) was seen in the HF-DC group as indicated by raised homeostasis model assessment of IR (HOMA-IR) in HF-DC group as compared with normal control (NC) groups. The treatment groups reduced IR as shown by a decrease in HOMA-IR as compared with HF-DC group rats. The marked reduction (P < 0.001) of beta-cell function was observed in the HF-DC group as a reduced level of HOMA for beta-cell function (HOMA-β) was found as compared with the NC group. Increases in HOMA-β as compared to the HFDC group were observed in the therapy groups. The treatment group significantly reduced cholesterol and atherogenic index. The treatment group showed significant preservation of beta-cell mass as per immunohistochemistry and significant anti-apoptotic activity as per Terminal Deoxyribonucleotidyl Transferase-Mediated dUTP Nick End Labeling assay report. The treated rats significantly (P < 0.05) reduced high-sensitivity C-reactive protein. Lipid peroxidation (thiobarbituric acid reactive substances) marker (P < 0.001) was significantly reduced in the treatment group. CONCLUSION: The natural DPP-IV inhibitors BER and MNG treatment showed beneficial effects on various components of metabolic syndrome. Wolters Kluwer - Medknow 2023 2023-09-25 /pmc/articles/PMC10666829/ /pubmed/38023603 http://dx.doi.org/10.4103/ijabmr.ijabmr_115_23 Text en Copyright: © 2023 International Journal of Applied and Basic Medical Research https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Suman, Rajesh Kumar
Borde, Manjusha K
Mohanty, Ipseeta Ray
Singh, Hemant Kumar
Mechanism of Action of Natural Dipeptidyl Peptidase-IV Inhibitors (Berberine and Mangiferin) in Experimentally Induced Diabetes with Metabolic Syndrome
title Mechanism of Action of Natural Dipeptidyl Peptidase-IV Inhibitors (Berberine and Mangiferin) in Experimentally Induced Diabetes with Metabolic Syndrome
title_full Mechanism of Action of Natural Dipeptidyl Peptidase-IV Inhibitors (Berberine and Mangiferin) in Experimentally Induced Diabetes with Metabolic Syndrome
title_fullStr Mechanism of Action of Natural Dipeptidyl Peptidase-IV Inhibitors (Berberine and Mangiferin) in Experimentally Induced Diabetes with Metabolic Syndrome
title_full_unstemmed Mechanism of Action of Natural Dipeptidyl Peptidase-IV Inhibitors (Berberine and Mangiferin) in Experimentally Induced Diabetes with Metabolic Syndrome
title_short Mechanism of Action of Natural Dipeptidyl Peptidase-IV Inhibitors (Berberine and Mangiferin) in Experimentally Induced Diabetes with Metabolic Syndrome
title_sort mechanism of action of natural dipeptidyl peptidase-iv inhibitors (berberine and mangiferin) in experimentally induced diabetes with metabolic syndrome
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10666829/
https://www.ncbi.nlm.nih.gov/pubmed/38023603
http://dx.doi.org/10.4103/ijabmr.ijabmr_115_23
work_keys_str_mv AT sumanrajeshkumar mechanismofactionofnaturaldipeptidylpeptidaseivinhibitorsberberineandmangiferininexperimentallyinduceddiabeteswithmetabolicsyndrome
AT bordemanjushak mechanismofactionofnaturaldipeptidylpeptidaseivinhibitorsberberineandmangiferininexperimentallyinduceddiabeteswithmetabolicsyndrome
AT mohantyipseetaray mechanismofactionofnaturaldipeptidylpeptidaseivinhibitorsberberineandmangiferininexperimentallyinduceddiabeteswithmetabolicsyndrome
AT singhhemantkumar mechanismofactionofnaturaldipeptidylpeptidaseivinhibitorsberberineandmangiferininexperimentallyinduceddiabeteswithmetabolicsyndrome